bioAffinity TechnologiesBIAF
BIAF
About: bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.
Employees: 75
0
Funds holding %
of 6,809 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
200% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 2
10% more capital invested
Capital invested by funds: $865K [Q2] → $952K (+$86.5K) [Q3]
0.04% less ownership
Funds ownership: 3.44% [Q2] → 3.39% (-0.04%) [Q3]
24% less funds holding
Funds holding: 17 [Q2] → 13 (-4) [Q3]
67% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 6
Research analyst outlook
We haven’t received any recent analyst ratings for BIAF.
Financial journalist opinion
Neutral
Business Wire
4 days ago
Join bioAffinity Technologies' Exclusive Live Investor Webinar and Q&A Session on Thursday, December 19
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies President and CEO Maria Zannes will be featured on RedChip Companies' investor webinar on Thursday, Dec. 19.
Neutral
Business Wire
1 week ago
bioAffinity Technologies Set for Continued Expansion in 2025
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity reports successful execution of its pilot marketing program and steady growth in sales of the CyPath® Lung test in 2024.
Neutral
Business Wire
1 month ago
bioAffinity Technologies Reports $2.4 Million Revenue for Q3 2024
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies releases financial results for the three months ended September 30, 2024.
Neutral
Business Wire
1 month ago
bioAffinity Technologies Appoints New Chief Science Officer to Spearhead Product Development
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies promotes Senior VP William Bauta, Ph.D., to Chief Science Officer to spearhead product development.
Neutral
Business Wire
1 month ago
bioAffinity Technologies Announces Award of Japanese Patent for CyPath® Lung
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies receives a Japanese patent for the method behind the CyPath® Lung diagnostic test for early-stage lung cancer.
Neutral
PRNewsWire
2 months ago
WallachBeth Capital Announces Closing of bioAffinity Technologies $2.6 Million Registered Direct Offering & Concurrent Private Placement
JERSEY CITY, N.J. , Oct. 21, 2024 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, has closed its previously announced registered direct offering with institutional investors for the purchase and sale of 2,048,294 shares (the "Shares") of common stock at a price of $1.30 per share and concurrent private placement of common warrants (the "Warrants") to purchase up to 2,662,782 shares of common stock at an exercise price of $1.50 per common share for gross proceeds of $2,662,782 before deducting placement agent fees and other offering expenses payable by the Company.
Neutral
Business Wire
2 months ago
bioAffinity Technologies Announces Closing of $2.6 Million Registered Direct Offering & Concurrent Private Placement
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies announces closing of $2.6 million registered direct offering and concurrent private placement.
Neutral
PRNewsWire
2 months ago
WallachBeth Capital Announces Pricing of bioAffinity Technologies $2.66 Million Registered Direct Offering & Concurrent Private Placement
JERSEY CITY, N.J. , Oct. 18, 2024 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that– bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, has entered into a securities purchase agreement with institutional investors for the purchase and sale of 2,048,294 shares (the "Shares") of common stock in a registered direct offering at a price of $1.30 per share and, in a concurrent private placement, common warrants (the "Warrants") to purchase up to 2,662,782 shares of common stock at an exercise price of $1.50 per common share.
Neutral
Business Wire
2 months ago
bioAffinity Technologies Announces Pricing of $2.66 Million Registered Direct Offering & Concurrent Private Placement
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies announces pricing of $2.66 million registered direct offering and concurrent private placement.
Neutral
Business Wire
2 months ago
bioAffinity's CyPath® Lung Cancer Test Supported by Newly Published Flow Cytometry Guidelines
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity VP served on expert panel to update flow cytometry guidelines for unique biological samples like sputum used in CyPath® Lung.
Charts implemented using Lightweight Charts™